Clinical Trial

Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma

Study acronym: ROMA
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, phase 2, randomized trial to compare rituximab maintenance with observation after rituximab and lenalidomide (R2) induction therapy in patients with previously untreated marginal zone lymphoma. Patients who achieve complete response or partial response after R2 induction will be randomized to receive rituximab maintenance or observation.
Trial Details
NCT Number NCT07654465
Lead Sponsor Sun Yat-sen University
Conditions Marginal Zone Lymphoma(MZL)
Enrollment 144 participants
Start Date 2026-07
Primary Completion 2030-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-17